Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jun;32(3):292-7.
doi: 10.1007/s12016-007-8005-6.

The future of biologic agents in the treatment of Sjögren's syndrome

Jiska M Meijer  1 , Justin Pijpe, Hendrika Bootsma, Arjan Vissink, Cees G M Kallenberg
Affiliations
Review

The future of biologic agents in the treatment of Sjögren's syndrome

Jiska M Meijer et al. Clin Rev Allergy Immunol. 2007 Jun.

Abstract

The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjögren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN- alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.

PubMed Disclaimer

References

    1. Hansen A, Lipsky PE, Dorner T (2005) Immunopathogenesis of primary Sjogren’s syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17:558–565 - DOI - PubMed
    1. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E et al (2004) Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum 50:1270–1276 - DOI - PubMed
    1. Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Harada K et al (2000) Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjogren’s syndrome salivary glands. Arthritis Rheum 43:1756–1767 - DOI - PubMed
    1. Cuello C, Palladinetti P, Tedla N, Di Girolamo N, Lloyd AR, McCluskey PJ et al (1998) Chemokine expression and leucocyte infiltration in Sjogren’s syndrome. Br J Rheumatol 37:779–783 - DOI - PubMed
    1. Matsumura R, Umemiya K, Goto T, Nakazawa T, Ochiai K, Kagami M et al (2000) Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 18:311–318 - PubMed

MeSH terms

Substances